DDAVP in childhood nocturnal enuresis
- PMID: 568870
- DOI: 10.1111/j.1651-2227.1978.tb16255.x
DDAVP in childhood nocturnal enuresis
Abstract
A double-blind study of 18 children aged 6--12 years suffering from primary nocturnal enuresis without signs of underlying organic disease is reported. 20 microgram of DDAVP (desamino-D-arginine vasopressin, Minirin) was given intranasally at bedtime. The effect was prompt and satisfactory in 8 children and relatively good in another 8 children. No adverse effects were noted. DDAVP is advocated for temporary use in children with nocturnal enuresis needing immediate help.